logo-loader
Genedrive PLC

US giant AbbVie to fund trial of genedrive's hep C test

genedrive thinks its simple out-reach test can help to cure hepatitis C in recovering heroin addicts, people who generally don’t like going to the doctors

hcv id kit
The two-year trial will cover up to 40 pharmacies across three sites in Scotland, Wales and Australia

genedrive PLC (LON:GDR) is to trial its hepatitis C (HCV) testing device in recovering heroin addicts as it looks to see if its diagnostic is cheaper and more effective than what is currently available on the market.

People undergoing treatment for opiate addiction are generally unlikely to travel too far to see a doctor, so genedrive thinks its easy-to-use, outreach kit could be particularly useful in this patient population.

READ: genedrive 'well-placed' after £6mln fundraise

The study will determine if more people with hepatitis C can be treated and cured and will also examine whether Genedrive HCV-ID is a more cost-effective option for the NHS in the UK and Medicare in Australia.

It will be funded by US biopharma giant AbbVie Inc (NYSE:ABBV) and is expected to last for two years and enrol around 140 patients.

“The advancement of molecular diagnostics to the point of need will provide faster treatment decisions to patients who have difficulty accessing traditional centralised services,” said chief executive David Budd.

“We see the requirement for Test and Treat outside of centralised services as a common theme across our menu targets. We are very pleased to be working with Professor Dillon in further proving the cost-effectiveness and clinical benefits of Genedrive HCV-ID in another near patient setting.”

John Dillon, who is leading the study, added: “It is vital that if we are to eliminate HCV, we must find novel ways of using paradigm shifting technology like Genedrive HCV-ID  in care pathways, to bring cure of HCV to the people who need it most.”

Quick facts: Genedrive PLC

Price: £0.17

Market: AIM
Market Cap: £5.78 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Genedrive PLC named herein, including the promotion by the Company of Genedrive PLC in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Genedrive PLC optimistic on the long-term opportunity for its HCV test

Genedrive PLC (LON:GDR) CEO David Budd tells Proactive London's Andrew Scott he remains confident the World Health Organisation will pre-qualify its HCV ID hepatitis C test in the near term despite some delays to the clinical trial. He adds that the development of an antibiotic-induced...

on 12/7/19

2 min read